Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance - Wikidata - awgldk - TriplyDB

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

http://www.wikidata.org/entity/Q28083239

about

Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance.Value of serum marker HE4 in pulmonary carcinoma diagnosis Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance.Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer.Activation of Epidermal Growth Factor Receptor/p38/Hypoxia-inducible Factor-1α Is Pivotal for Angiogenesis and Tumorigenesis of Malignantly Transformed Cells Induced by Hexavalent Chromium.Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.

P2860

Q35792090-0D1C1987-C827-4C25-BA68-5BBF1B2543D7 Q36412094-0F6B1464-E1B4-4F73-ABEF-ADC540B86013 Q36532224-BC086DE1-603E-4EE5-88CB-B007849EEB8D Q41989407-6174772A-C9AE-41DA-925B-94343F727675 Q42267604-726612A0-8B49-4A9C-ABC1-B0C4964BA80E Q42395477-A174EA32-13A0-4F3E-98AB-69054C7F1FE9 Q47220604-83CD3414-3904-4C97-ABEA-E37CFFA2A764 Q47574122-6706692F-A14A-4843-BA42-121E1A288EB4

P2860

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

http://www.wikidata.org/entity/Q28083239

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@ast

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@en

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@nl

type

label

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@ast

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@en

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@nl

prefLabel

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@ast

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@en

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@nl

P1433

Q28083239-81D82E4A-7104-4059-B91E-E9FC7B742A79

P1476

Q28083239-C41DF332-0F9F-4467-A17C-A13FF36DF6BD

P2093

Q28083239-2A4D4280-D17E-453E-A438-9F7CFE992FEF

Q28083239-F0C0BAFF-F3D4-4C74-944A-1E7E20215E67

P2860

Q28083239-0192475C-1CC0-4882-B5B4-3D5A09A29E85

Q28083239-07C4B546-A5C4-45A0-B085-230AA2518E3A

Q28083239-08DEE06C-9D35-4F00-AA7E-3A4529757BDF

Q28083239-09D1380C-AE06-40FF-A2AA-9910723F8FEB

Q28083239-0E4F461F-F0C0-4558-A8AF-E848F7F7EC90

Q28083239-16168094-376C-415C-AAED-DA535FAAE599

Q28083239-1708D884-388F-4BB5-B53B-64E8B154174E

Q28083239-17559BBA-18D6-4A74-A81A-6647973A6E9C

Q28083239-1BFA3B9A-AC34-4C98-87ED-58EEECA18627

Q28083239-1C5FECD1-DF2E-4B1C-8522-883E14210973

P304

Q28083239-AF0E5181-A8DF-48EB-9D14-27D1483BD0C6

P31

Q28083239-C71637A7-A3FF-426E-9906-DED663DEC144

P356

Q28083239-2C234C75-CB1D-4803-8C3B-783708DADA91

P407

Q28083239-BD94D558-73A3-4D5C-83C6-4A35CF548031

P433

Q28083239-B89DE5B1-8572-41A1-A551-3EEB993EBC6B

P478

Q28083239-568A198B-9BD1-412A-AB02-DB970D1B3E0E

P577

Q28083239-106AD8C9-E527-4BDC-A712-682280DBEE45

P5875

Q28083239-22E6DBB1-9366-45B5-A2D8-6FEF8673F75D

P698

Q28083239-4EE0948B-BC37-4026-AC5F-6B4C62526637

P932

Q28083239-8B12EA0F-B5BA-4100-8BE1-426D85732FAB

P356

P1433

Journal of personalized medicine

P1476

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

@en

P2093

Wen-Shuo Wu

http://www.w3.org/2001/XMLSchema#string

Yuh-Min Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Lung cancer in 2013: state of the art therapy for metastatic disease

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

P304

297-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JPM4030297

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270662754

http://www.w3.org/2001/XMLSchema#string

P698

25563355

http://www.w3.org/2001/XMLSchema#string

P932

4263962

http://www.w3.org/2001/XMLSchema#string